{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:59:26Z","timestamp":1791932366680,"version":"4.3.4"},"reference-count":21,"publisher":"Elsevier BV","issue":"48","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T00:00:00Z","timestamp":1537488000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.vaccine.2018.09.009","type":"journal-article","created":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T21:54:00Z","timestamp":1537912440000},"page":"7171-7177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Safety of the rVSV ZEBOV vaccine against Ebola Zaire among frontline workers in Guinea"],"prefix":"10.1016","volume":"37","author":[{"given":"Aitana","family":"Juan-Giner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Tchaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Jemmy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aboubacar","family":"Soumah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yap","family":"Boum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta Maria","family":"Faga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Cisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca F.","family":"Grais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.09.009_b0005","unstructured":"WHO. Ebola Situation Report \u2013 29 July 2015; 2015 [cited 2015 Jul 31]. Available from: http:\/\/apps.who.int\/ebola\/current-situation\/ebola-situation-report-29-july-2015."},{"issue":"9996","key":"10.1016\/j.vaccine.2018.09.009_b0010","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0140-6736(15)61117-5","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial","volume":"386","author":"Henao-Restrepo","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.09.009_b0015","unstructured":"WHO. Health worker Ebola infections in Guinea, Liberia and Sierra Leone. World Health Organization; 2015 [cited 2015 Jul 31]. Available from: http:\/\/www.who.int\/csr\/resources\/publications\/ebola\/health-worker-infections\/en\/."},{"key":"10.1016\/j.vaccine.2018.09.009_b0020","unstructured":"International Conference on Harmonization. ICH E6: Good Clinical Practice: Consolidates guideline. Directive 75\/318\/EEC as amended. 1997."},{"issue":"5\u20136","key":"10.1016\/j.vaccine.2018.09.009_b0025","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.vaccine.2003.09.007","article-title":"Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation","volume":"22","author":"Marcy","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.09.009_b0030","first-page":"1647","article-title":"Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe \u2014 preliminary report","volume":"347","author":"Agnandji","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.vaccine.2018.09.009_b0035","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1473-3099(15)00154-1","article-title":"The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1\/2 trial","volume":"15","author":"Huttner","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2018.09.009_b0040","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1414216","article-title":"A recombinant vesicular stomatitis virus Ebola vaccine","volume":"376","author":"Regules","year":"2017","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.vaccine.2018.09.009_b0045","first-page":"32621","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)","volume":"6737","author":"Henao-restrepo","year":"2016","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.vaccine.2018.09.009_b0050","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMoa1502924","article-title":"Phase 1 trials of rVSV Ebola vaccine in Africa and Europe","volume":"374","author":"Agnandji","year":"2016","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.vaccine.2018.09.009_b0055","doi-asserted-by":"crossref","first-page":"e1002402","DOI":"10.1371\/journal.pmed.1002402","article-title":"Safety and immunogenicity of rVSVDeltaG-ZEBOV-GP Ebola vaccine in adults and children in Lambarene, Gabon: a phase I randomised trial","volume":"14","author":"Agnandji","year":"2017","journal-title":"PLoS Med"},{"issue":"8","key":"10.1016\/j.vaccine.2018.09.009_b0060","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S1473-3099(17)30313-4","article-title":"Safety and immunogenicity of the rVSVG-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study","volume":"17","author":"Heppner","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"15","key":"10.1016\/j.vaccine.2018.09.009_b0065","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1056\/NEJMoa1614067","article-title":"Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in Liberia","volume":"377","author":"Kennedy","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.vaccine.2018.09.009_b0070","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S1473-3099(15)00486-7","article-title":"Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1\/2a study","volume":"16","author":"De Santis","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"17","key":"10.1016\/j.vaccine.2018.09.009_b0075","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1056\/NEJMoa1411627","article-title":"A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA","volume":"374","author":"Ewer","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.vaccine.2018.09.009_b0080","doi-asserted-by":"crossref","first-page":"4","DOI":"10.32607\/20758251-2017-9-3-4-11","article-title":"Virus-vectored Ebola vaccines","volume":"9","author":"Dolzhikova","year":"2017","journal-title":"Acta Naturae"},{"issue":"9","key":"10.1016\/j.vaccine.2018.09.009_b0085","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1080\/21645515.2017.1342021","article-title":"Open-label phase I clinical trial of Ad5-EBOV in Africans in China","volume":"13","author":"Wu","year":"2017","journal-title":"Hum Vaccines Immunother"},{"issue":"52","key":"10.1016\/j.vaccine.2018.09.009_b0090","doi-asserted-by":"crossref","first-page":"7057","DOI":"10.1016\/j.vaccine.2014.09.052","article-title":"Safety of immunization during pregnancy: a review of the evidence of selected inactivated and live attenuated vaccines","volume":"32","author":"Keller-Stanislawski","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.09.009_b0095","unstructured":"WHO. Ebola virus disease in pregnancy: Screening and management of Ebola cases, contacts and survivors. Interim Guidance. WHO\/EVD\/HSE\/PED\/15.1; 2015. p. 1\u20134."},{"key":"10.1016\/j.vaccine.2018.09.009_b0100","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/cid\/civ1024","article-title":"Dilemmas in managing pregnant women with Ebola: 2 case reports","volume":"62","author":"Caluwaerts","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2018.09.009_b0105","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1177\/1753495X15597354","article-title":"Ebola viral disease and pregnancy","volume":"8","author":"Black","year":"2015","journal-title":"Obstet Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18312465?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18312465?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T22:20:51Z","timestamp":1573165251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18312465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":21,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0264410X18312465"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.09.009","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of the rVSV ZEBOV vaccine against Ebola Zaire among frontline workers in Guinea","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}